阿贝西利联合非甾体芳香化酶抑制剂作为HR+、HER2-晚期乳腺癌初始治疗的最终总生存结果:MONARCH 3研究
MONARCH 3是一项随机双盲III期研究,比较阿贝西利联合非甾体芳香化酶抑制剂(NSAI)与安慰剂联合NSAI用于无既往晚期系统治疗的内分泌治疗后绝经女性HR+、HER2-晚期乳腺癌。中位随访8.1年,总生存(OS)风险比0.804(95%CI 0.637-1.015;P=0.0664,未达统计学显著),中位OS阿贝西利组66.8个月 vs 安慰剂组53.7个月。
要点
- 中位随访8.1年,阿贝西利组OS事件198例(60.4%),安慰剂组116例(70.3%)。
- 中位OS阿贝西利组66.8个月 vs 安慰剂组53.7个月,HR 0.804(95%CI 0.637-1.015;P=0.0664,未达统计学显著)。
- 内脏转移亚组中位OS阿贝西利组63.7个月 vs 安慰剂组48.8个月,HR 0.758(95%CI 0.558-1.030;P=0.0757,未达统计学显著)。
核心结论
- 阿贝西利联合NSAI在HR+、HER2-晚期乳腺癌中带来中位OS的临床意义改善(意向治疗人群13.1个月;内脏转移亚组14.9个月),但未达到统计学显著。
研究设计与样本
- MONARCH 3为随机、双盲、III期研究,比较阿贝西利联合NSAI(阿那曲唑或来曲唑)与安慰剂联合NSAI,用于无既往晚期系统治疗的绝经后HR+、HER2-晚期乳腺癌女性。
- 共493例女性按2:1随机分配至阿贝西利联合NSAI组(n=328)或安慰剂联合NSAI组(n=165)。
- 主要终点为研究者评估的无进展生存(PFS);OS为门控次要终点,无化疗生存为探索性终点。
主要发现
- 中位随访8.1年,阿贝西利组OS事件198例(60.4%),安慰剂组116例(70.3%);HR 0.804(95%CI 0.637-1.015;P=0.0664,未达统计学显著)。
- 中位OS阿贝西利组66.8个月 vs 安慰剂组53.7个月。
- 内脏转移亚组中,阿贝西利组OS事件113例(65.3%),安慰剂组65例(72.2%);HR 0.758(95%CI 0.558-1.030;P=0.0757,未达统计学显著)。
- 内脏转移亚组中位OS阿贝西利组63.7个月 vs 安慰剂组48.8个月。
- 既往显示的PFS获益持续存在,加用阿贝西利后无化疗生存数值上改善;未观察到新的安全性信号。
局限性
- OS未达到统计学显著(HR 0.804;95%CI 0.637-1.015;P=0.0664)。
- 内脏转移亚组OS未达到统计学显著(HR 0.758;95%CI 0.558-1.030;P=0.0757)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with disease progression on prior endocrine therapy. In MONARCH 3, the addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for HR+, HER2- ABC significantly improved PFS. Here, we present the prespecified final OS results for MONARCH 3. PATIENTS AND METHODS: MONARCH 3 is a randomized, double-blind, phase III study of abemaciclib plus NSAI (anastrozole or letrozole) versus placebo plus NSAI in postmenopausal women with HR+, HER2- ABC without prior systemic therapy in the advanced setting. The primary objective was investigator-assessed PFS; OS was a gated secondary endpoint, and chemotherapy-free survival was an exploratory endpoint. RESULTS: A total of 493 women were randomized 2 : 1 to receive abemaciclib plus NSAI (n = 328) or placebo plus NSAI (n = 165). After a median follow-up of 8.1 years, there were 198 OS events (60.4%) in the abemaciclib arm and 116 (70.3%) in the placebo arm (hazard ratio, 0.804; 95% confidence interval 0.637-1.015; P = 0.0664, non-significant). Median OS was 66.8 versus 53.7 months for abemaciclib versus placebo. In the subgroup with visceral disease, there were 113 OS events (65.3%) in the abemaciclib arm and 65 (72.2%) in the placebo arm (hazard ratio, 0.758; 95% confidence interval 0.558-1.030; P = 0.0757, non-significant). Median OS was 63.7 months versus 48.8 months for abemaciclib versus placebo. The previously demonstrated PFS benefit was sustained, and chemotherapy-free survival numerically improved with the addition of abemaciclib. No new safety signals were observed. CONCLUSIONS: Abemaciclib combined with an NSAI resulted in clinically meaningful improvement in median OS (intent-to-treat population: 13.1 months; subgroup with visceral disease: 14.9 months) in patients with HR+ HER2- ABC; however, statistical significance was not reached.
引用
- Goetz MP, Toi M, Huober J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024. PMID: 38729566. doi:10.1016/j.annonc.2024.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。